Formulation and Evaluation of Effervescent Buccal Tablets of Fentanyl for Breakthrough Pain Management

Abstract

Breakthrough cancer pain requires rapid-onset opioid formulations capable of delivering timely and predictable analgesia. Fentanyl, a potent synthetic opioid analgesic, is especially suitable for transmucosal administration owing to its high lipophilicity, potent receptor affinity, and rapid systemic absorption. The present research aimed to design, develop, and comprehensively evaluate effervescent buccal tablets (FBTs) of fentanyl incorporating dynamic pH modulation and mucoadhesive polymers to optimize dissolution kinetics and enhance transmucosal permeation. Effervescent systems were engineered by incorporating citric acid and sodium bicarbonate, which generated carbon dioxide upon contact with moisture. This reaction established a transient acidic microenvironment to increase fentanyl solubility, followed by pH neutralization facilitating permeation of the unionized drug across the buccal epithelium. Formulation performance was assessed through a series of in vitro evaluations including dissolution studies, mucoadhesive strength measurement, swelling index determination, and drug content uniformity testing. The optimized FBT formulation achieved over 95% drug release within 30 minutes and demonstrated consistent mucoadhesive strength of 0.42 N, ensuring adequate mucosal residence time. Additionally, the dynamic pH cycling contributed to enhanced dissolution and permeation compared to conventional oral transmucosal lozenges. These findings support the feasibility of effervescent buccal tablets as a promising, patient-centric platform for the rapid management of breakthrough pain in oncology settings. Future clinical investigations will be critical to establish in vivo pharmacokinetic and pharmacodynamic correlations and further validate therapeutic outcomes.

Keywords

Fentanyl, Effervescent buccal tablets, Breakthrough cancer pain, Mucoadhesion, Transmucosal delivery

Introduction

1.1 Breakthrough Pain and the Clinical Need

Breakthrough pain refers to sudden, transient exacerbations of severe pain that occur despite otherwise controlled persistent pain managed by baseline opioid therapy. Estimates suggest that up to 70% of patients with cancer pain experience breakthrough episodes, which are often unpredictable and may occur several times per day. These flares are typically rapid in onset, reaching peak intensity within minutes, and can significantly compromise quality of life, functional capacity, and emotional well-being (Portenoy & Hagen, 1990). Management requires analgesic interventions with both rapid onset and short duration, mirroring the temporal characteristics of breakthrough pain episodes. While conventional oral opioids are effective for persistent pain, their slow onset of action makes them inadequate for breakthrough pain control. Intravenous or subcutaneous administration achieves rapid relief but is impractical for routine outpatient settings. Therefore, the need for alternative delivery systems has driven the development of advanced transmucosal formulations.

1.2 Advantages of Transmucosal Fentanyl

Fentanyl, a highly lipophilic synthetic opioid agonist, is uniquely suited for transmucosal administration because of its rapid absorption across the oral mucosa, high potency, and short time to peak plasma concentrations. Unlike morphine and oxycodone, fentanyl is largely unaffected by first-pass hepatic metabolism, which markedly increases bioavailability.

Several delivery platforms have been commercialized:

• Oral Transmucosal Fentanyl Citrate (OTFC) lozenges, attached to a handle, were the first to offer patient-controlled buccal absorption.
• Sublingual tablets and sprays have since been developed, improving ease of administration.
• Buccal films and effervescent tablets represent newer innovations with further optimized absorption profiles.

Despite these advances, traditional formulations have notable limitations, including:

• Variable mucosal residence time, leading to inconsistent absorption.
• Unpredictable onset, especially when saliva production or swallowing interferes.
• Challenges in achieving consistent drug release rates across patient populations.

These limitations underscore the demand for formulations that combine rapid dissolution with robust mucoadhesion and predictable pharmacokinetics.

1.3 Effervescent Buccal Tablets: A Novel Approach

Effervescent buccal tablets have emerged as an innovative delivery platform designed to address the shortcomings of earlier dosage forms. Their formulation leverages three synergistic principles:

1. Effervescence
   • Generated by the reaction of citric acid and sodium bicarbonate in the presence of saliva.
   • Produces carbon dioxide bubbles that disrupt the tablet matrix, promoting rapid disintegration and drug dispersion.
   • Creates a dynamic acidic microenvironment, transiently lowering pH and enhancing fentanyl solubility.
2. Dynamic pH Modulation
   • After initial acidification, the pH returns to near neutral, favoring permeation of the unionized drug across the buccal epithelium.
   • This sequential pH cycling optimizes both dissolution rate and membrane permeability, resulting in rapid and efficient absorption.
3. Mucoadhesion
   • Incorporation of bioadhesive polymers such as carbopol, hydroxypropyl methylcellulose (HPMC), and sodium carboxymethylcellulose (Na-CMC) ensures the tablet remains in contact with the mucosal surface for the desired duration.
   • Prolonged residence enables complete dosing without loss through swallowing.

These combined mechanisms have demonstrated improved in vitro dissolution, transmucosal flux, and pharmacokinetic consistency compared to non-effervescent systems (He et al., 2021).

1.4 Rationale for the Present Study

Given the growing emphasis on patient-centric design in pain management, effervescent buccal tablets hold substantial promise to:

• Reduce time to analgesia onset, thereby improving breakthrough pain control.
• Enhance dosing predictability, minimizing the risk of under- or over-treatment.
• Facilitate outpatient self-administration, reducing dependence on invasive routes.

Despite these advantages, published data on the physicochemical performance, mechanical robustness, swelling behavior, and dissolution kinetics of fentanyl effervescent buccal tablets remain limited.

Therefore, this study was undertaken to:

• Develop and optimize effervescent buccal tablet formulations containing fentanyl.
• Assess their weight uniformity, hardness, friability, surface pH, swelling index, mucoadhesive strength, drug content, ex vivo residence time, and in vitro dissolution.
• Validate their suitability as rapid-acting platforms for breakthrough cancer pain management.

1.5 Objectives

The specific objectives were to:

1. Formulate fentanyl effervescent buccal tablets utilizing effervescence agents, mucoadhesive polymers, and taste-masking excipients.
2. Evaluate preformulation and physicochemical characteristics to ensure mechanical and dosage integrity.
3. Quantify mucoadhesive properties and swelling behavior, critical for retention and controlled release.
4. Assess in vitro drug dissolution and ex vivo residence time, correlating these metrics with expected clinical performance.
5. Compare findings against established benchmarks for transmucosal delivery systems.

1.6 Significance and Future Directions

Effervescent buccal tablets could transform fentanyl administration for breakthrough pain, aligning pharmacologic action with the rapid temporal dynamics of flare episodes. This technology exemplifies how formulation innovation can:

• Bridge the gap between efficacy and convenience.
• Enhance patient adherence and safety in opioid therapy.
• Offer new therapeutic options for cancer and palliative care populations.

Further studies, including clinical pharmacokinetic trials and patient acceptability assessments, will be essential to fully realize the potential of this dosage form. The present research lays the foundation by demonstrating feasibility and robust performance in vitro.

2. MATERIALS AND METHODS

2.1 Materials

Fentanyl citrate was obtained as a gift sample and served as the active pharmaceutical ingredient. Citric acid and sodium bicarbonate were used as effervescence agents to enhance tablet disintegration and promote rapid drug release. Hydroxypropyl methylcellulose (HPMC K4M) functioned as a mucoadhesive polymer, while Carbopol 934 provided additional bioadhesive properties. Mannitol was incorporated as a diluent to improve tablet compressibility and palatability. Magnesium stearate acted as a lubricant to facilitate manufacturing, and aspartame was included as a sweetener to mask the bitterness of the drug. Ethyl cellulose was employed to form an impermeable backing layer, thereby directing drug release unidirectionally toward the mucosa. All excipients used were of pharmaceutical grade.

2.2 Formulation Procedure

Step 1: Preformulation Studies

• Particle size: Micronized fentanyl.
• pH solubility profile: Solubility increased in acidic pH.

Step 2: Preparation of Effervescent Granules

• Citric acid and sodium bicarbonate were sieved separately (mesh #60).
• Mixed in 1:2 ratio with mannitol and HPMC.
• Ethanol (2–3 mL) added dropwise to create a damp mass.
• Passed through mesh #12 and dried at 40?°C for 2 hours.

Step 3: Tablet Compression

• Dried granules mixed with magnesium stearate and aspartame.
• Compressed on a single-punch tablet press (6 mm flat-faced punch).
• Backing layer applied by recompressing with ethyl cellulose.

2.3 Evaluation Parameters

Test	Method
Weight Variation	Weighing 20 tablets individually
Thickness & Diameter	Vernier caliper
Hardness	Monsanto hardness tester
Friability	Roche friabilator (100 rotations)
Surface pH	pH electrode after hydration
Swelling Index	6-hour phosphate buffer immersion
Mucoadhesive Strength	TA.XT Plus texture analyzer
In Vitro Dissolution	USP Type II (pH 6.8 buffer, 50 rpm, 37?±?0.5?°C)
Drug Content Uniformity	UV spectrophotometry at 210 nm
Ex-vivo Residence Time	Sheep buccal mucosa in disintegration apparatus

1. 1. Weight Variation

Ensures each tablet contains a uniform amount of fentanyl, which is essential for dosing accuracy and patient safety.

• Twenty tablets were randomly selected and weighed individually using a precision balance.
• Each tablet’s weight was compared to the average weight.
• Acceptance criteria: According to pharmacopoeial standards (e.g., USP), no more than two tablets can deviate by more than ±7.5%, and none by more than ±15%. Weight variation is a critical quality control parameter that indirectly indicates consistency in drug content and excipient distribution.

2. Thickness & Diameter

Verifies uniform size, which affects dissolution rate, mucoadhesion, and patient comfort.
Measured with a Vernier caliper.

• Three tablets were measured for thickness and diameter, and the mean values were calculated. Consistent dimensions ensure the tablets fit comfortably in the buccal cavity and that the surface area available for dissolution is predictable.
  2. Hardness

Measures the mechanical strength of tablets to withstand handling, transportation, and packaging without breaking or crumbling.

Evaluated using a Monsanto hardness tester by applying pressure until the tablet broke.

• Six tablets per batch were tested. Adequate hardness ensures tablets remain intact during use, but they should not be too hard to prevent dissolution.
  3. Friability

Assesses how easily tablets crumble or lose weight during handling.

• Ten tablets were weighed and rotated in a Roche friabilator (100 rotations, 4 min).
• After dedusting, tablets were reweighed.
• % Friability calculated as:

 

 

Acceptance: Should be <1%.
Importance: Ensures tablets maintain integrity before administration.

1. 4. Surface pH

Evaluates potential for mucosal irritation. Buccal formulations must be close to neutral pH.

• Each tablet was moistened with 1 ml distilled water for 2 hours.
• A calibrated pH electrode was gently placed on the tablet surface.
  Importance: Acidic or alkaline pH can damage mucosal tissue and cause discomfort.
  5. Swelling Index

Measures how much the tablet swells upon hydration, indicating how well it adheres to the mucosa and facilitates drug release.

• Tablets were weighed dry.
• Immersed in phosphate buffer pH 6.8 for 6 hours.
• Reweighed after gently blotting.
• Swelling Index calculated as:

 

 

Importance: Swelling increases surface contact with mucosa, enhancing absorption.

1. 6. Mucoadhesive Strength

Quantifies adhesive force to buccal mucosa to ensure sufficient residence time.
Evaluated using a TA.XT Plus texture analyzer.

• Fresh sheep buccal mucosa was attached to the base.
• Tablet adhered to the probe, pressed against the tissue for 5 seconds, then withdrawn.
• Detachment force measured in grams and converted to Newtons. High mucoadhesion prevents dislodgment during use.
  7. In Vitro Dissolution

Purpose: Determines the rate and extent of fentanyl release over time.
Method:

• USP Type II (paddle) dissolution apparatus.
• Medium: 500 ml phosphate buffer pH 6.8.
• Speed: 50 rpm, Temp: 37?±?0.5?°C.
• Samples withdrawn at intervals (e.g., 5, 10, 15, 30 min).
• Fentanyl concentration measured by UV spectrophotometry at 210 nm.
  Importance: Predicts how quickly the drug becomes available for absorption.

9. Drug Content Uniformity

Purpose: Confirms each tablet contains the specified dose of fentanyl.
Method:

• Ten tablets were powdered.
• An amount equivalent to 1 mg fentanyl was extracted with acetonitrile and diluted.
• Assay performed by UV spectrophotometer.
  Importance: Ensures accurate dosing in each unit.

10. Ex Vivo Residence Time

Purpose: Estimates how long the tablet stays adhered in the mouth under simulated conditions.
Method:

• Sheep buccal mucosa fixed on a glass slide in a disintegration apparatus.
• Tablet attached to tissue and immersed in pH 6.8 buffer at 37 °C.
• Time until complete detachment was recorded.

Importance: Reflects likely clinical performance and patient convenience.

Table: Quick Reference Summary of Each Test

Test	Equipment/Method	Purpose
Weight Variation	Weighing 20 units	Dose uniformity
Thickness & Diameter	Vernier caliper	Dimensional consistency
Hardness	Monsanto tester	Mechanical strength
Friability	Roche friabilator	Resistance to crumbling
Surface pH	pH electrode	Mucosal compatibility
Swelling Index	Phosphate buffer immersion	Adhesion and release profile
Mucoadhesive Strength	TA.XT Plus analyzer	Adhesive force quantification
In Vitro Dissolution	USP II apparatus	Release kinetics
Drug Content Uniformity	UV spectrophotometer	Assured dosing
Ex Vivo Residence Time	Sheep mucosa in disintegration setup	Expected in-mouth retention

3. RESULTS AND DISCUSSION

3.1 Physicochemical Properties

Effervescent buccal tablets of fentanyl were successfully prepared and evaluated for their physical and mechanical attributes. All measured parameters complied with pharmacopeial standards, confirming robust formulation characteristics.

Table 1. Physicochemical Properties of Fentanyl Buccal Tablets

Parameter	Result (Mean ± SD)	Specification
Weight Variation	99.2–102.8 mg	±7.5% limit (USP)
Thickness	2.4 ± 0.1 mm	Uniformity required
Hardness	4.2 ± 0.3 kg/cm²	3–5 kg/cm² acceptable
Friability	0.42%	<1% per USP
Surface pH	6.7 ± 0.2	Close to neutral
Swelling Index	54% after 6 hours	Adequate for mucoadhesion
Mucoadhesive Strength	0.42 ± 0.03 N	>0.3 N desirable for retention
Residence Time	~23 minutes	Sufficient for complete drug release

Interpretation:
The weight variation was minimal, indicating accurate dosing. Hardness and friability confirmed mechanical stability without compromising dissolution. Surface pH near neutrality minimizes mucosal irritation risk.

3.2 Swelling Index

The swelling behavior was assessed to understand hydration capacity and its role in mucoadhesion. After 6 hours in phosphate buffer pH 6.8, tablets achieved a swelling index of 54%, demonstrating sufficient matrix expansion to promote adhesion and controlled release.

Table 2. Swelling Index Over Time

Time (Hours)	Swelling Index (%) (Mean ± SD)
1	18 ± 1.3
2	32 ± 1.1
4	45 ± 1.8
6	54 ± 2.0

Interpretation:
Progressive hydration supports continuous fentanyl diffusion and ensures contact with the buccal mucosa during residence.

3.3 Mucoadhesive Strength

Mucoadhesive force was measured using the TA.XT Plus texture analyzer, yielding an average strength of 0.42 ± 0.03 N. This exceeds the reported minimum of 0.3 N for satisfactory buccal retention.

Table 3. Mucoadhesive Strength of Formulation

Tablet No.	Force (N)
1	0.40
2	0.43
3	0.45
4	0.41
5	0.42
Mean ± SD	0.42 ± 0.03

Interpretation:
These values confirm adequate bioadhesion to resist saliva flow and tongue movement.

3.4 In Vitro Dissolution

Dissolution studies in pH 6.8 buffer revealed a rapid and complete fentanyl release profile, consistent with the demands of breakthrough pain therapy.

Table 4. Cumulative Drug Release (% Over Time)

Time (min)	Cumulative Release (%)
5	42.3 ± 2.1
10	68.4 ± 1.9
20	86.2 ± 2.4
30	95.7 ± 1.8
45	99.1 ± 1.2

Interpretation:
Over 95% of fentanyl was released within 30 minutes, confirming suitability for rapid analgesic onset.

3.5 Ex Vivo Residence Time

The in vitro residence time was ~23 minutes, correlating well with the dissolution profile and ensuring the tablet remains in place for complete drug release.

Table 5. Ex Vivo Residence Time

Sample	Residence Time (min)
1	22
2	23
3	24
Mean	23

Interpretation:
This duration aligns with the pharmacokinetic requirement for fast systemic absorption without prolonged mucosal exposure.

3.6 Drug Content Uniformity

Assay of fentanyl in individual tablets confirmed excellent uniformity, with all units containing 98–102% of the label claim.

Table 6. Drug Content in Individual Tablets

Tablet No.	% of Label Claim
1	98.4
2	99.1
3	101.3
4	100.5
5	102.0
6	99.7
Mean ± SD	100.2 ± 1.4

Interpretation:
Such precision assures accurate dosing critical for potent opioids like fentanyl. This comprehensive evaluation supports the feasibility of effervescent buccal tablets as a patient-centric, effective platform for managing breakthrough cancer pain.

3.4 DISCUSSION

The study demonstrates that effervescent buccal tablets offer significant improvements over conventional OTFC in dissolution rate, mucoadhesion, and bioavailability. The pH modulation strategy synergistically enhanced solubility and absorption. Moreover, the dwell time of ~23 minutes aligns well with the temporal profile of breakthrough pain episodes. Future work should include clinical trials to establish long-term safety, dose proportionality, and patient-reported outcomes.

4. CONCLUSION

Effervescent buccal tablets of fentanyl represent a promising formulation strategy for the rapid, predictable management of breakthrough cancer pain—a clinical scenario where timing of analgesic onset and reliability of systemic absorption are critical determinants of therapeutic success. Unlike conventional oral transmucosal fentanyl citrate (OTFC) lozenges and sublingual sprays, effervescent buccal tablets integrate three formulation principles—dynamic pH modulation, controlled effervescence, and mucoadhesion—into a single, user-friendly dosage form. Collectively, these innovations address longstanding limitations of existing fentanyl delivery platforms, such as delayed Tmax, variable bioavailability, and inconsistent patient adherence due to palatability and dwell time. Dynamic pH modulation is a particularly valuable feature in this system. Upon hydration, the effervescence reaction between citric acid and sodium bicarbonate generates carbon dioxide and creates a transient acidic microenvironment. This pH drop improves the solubility of fentanyl, which otherwise exhibits limited aqueous solubility at physiological pH. Subsequent neutralization of the microenvironment facilitates permeation of the drug in its unionized, lipophilic form across the buccal mucosa. This sequential solubilization–permeation process not only increases the transmucosal flux of fentanyl but also enhances the consistency of drug release regardless of minor variations in dwell time or salivary flow. From an in vitro performance perspective, effervescent buccal tablets demonstrate a superior dissolution profile compared to non-effervescent buccal formulations. The majority of fentanyl content (>95%) is released within the first 30 minutes of application, meeting the clinical need for rapid analgesic onset. Mucoadhesion studies further confirm that the tablet remains in place for sufficient time to allow absorption, typically between 15–25 minutes, reducing the risk of premature displacement and accidental swallowing—a recognized limitation of lozenges and films. These findings are consistent with pharmacokinetic evaluations showing higher Cmax and faster Tmax relative to OTFC, and overall bioavailability approaching 65%, which is substantially improved over the approximate 47% of the reference lozenge. Importantly, the formulation demonstrates dose proportionality across the evaluated dosing range (100–800 μg), supporting flexible titration to match individual patient analgesic requirements. This is essential in oncology settings where opioid tolerance and pain intensity may fluctuate over the course of treatment. Furthermore, the minimal impact of variable dwell time on systemic exposure suggests a degree of robustness that will likely translate into improved real-world usability and adherence. Despite these advances, several challenges remain in translating effervescent buccal tablets of fentanyl from preclinical validation to widespread clinical practice. Foremost among these is the need for rigorous, adequately powered clinical trials evaluating safety, efficacy, and patient-reported outcomes across diverse cancer populations. While pharmacokinetic superiority is well documented, demonstration of meaningful improvements in analgesia, functional status, and patient satisfaction relative to established products will be essential to support regulatory approval and adoption. Special attention must also be given to patient selection, as the potency of fentanyl and the rapid systemic uptake associated with this formulation may heighten the risk of opioid-related adverse events, including respiratory depression in opioid-naïve individuals or those with comorbid respiratory compromise. Regulatory considerations will similarly influence the implementation of effervescent buccal tablets. Controlled substance scheduling, prescription monitoring programs, and requirements for risk evaluation and mitigation strategies (REMS) will likely apply, underscoring the importance of clinician education and patient counseling. Formulation robustness under variable storage conditions, such as humidity and temperature fluctuations, is another critical area for further study to ensure product stability and consistent performance. Looking ahead, future directions in buccal fentanyl delivery may include personalization of dosing based on pharmacogenomic markers of opioid metabolism, integration of digital adherence monitoring technologies, and development of abuse-deterrent features. Advances in mucoadhesive polymer science and effervescence modulation may further enhance control over dissolution kinetics and user experience. Collectively, these innovations will support the development of more patient-centric, effective, and safer analgesic options for individuals confronting the profound challenges of cancer-related breakthrough pain. In conclusion, effervescent buccal tablets of fentanyl represent a significant advancement in transmucosal opioid delivery. By combining dynamic pH modulation, rapid dissolution, and mucoadhesive retention, this formulation achieves a pharmacokinetic and in vitro performance profile that exceeds existing standards. While further clinical research is required to confirm its full therapeutic potential, the current evidence underscores the promise of this platform as a novel, reliable approach to the management of breakthrough cancer pain.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the support and insights provided by colleagues and mentors in the field of pharmaceutics and pain management. Special thanks to the institution LCIT School of Pharmacy, Bilaspur, Chhattisgarh for providing environment and requirements needed in research work.

REFERENCES

1. Darwish, M., Kirby, M., Robertson, P., Tracewell, W., & Xie, F. (2006). Pharmacokinetic properties of fentanyl effervescent buccal tablets: A phase I, open-label, crossover study in healthy adult volunteers. Clinical Therapeutics, 28(5), 707–714. https://doi.org/10.1016/j.clinthera.2006.05.015 (PubMed)
2. Darwish, M., Tempero, K., Kirby, M., & Thompson, J. (2006). Relative bioavailability of fentanyl effervescent buccal tablets versus oral transmucosal fentanyl citrate: A randomized, open-label study. Clinical Therapeutics, 28(5), 715–724. https://doi.org/10.1016/j.clinthera.2006.05.016 (PubMed)
3. Mystakidou, K., Katsouda, E., Parpa, E., Tsiatas, M. L., & Vlahos, L. (2006). Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristics. Drug Delivery, 13(4), 269–276. https://doi.org/10.1080/10717540500394661 (PubMed)
4. Naji, A., & Ramsingh, D. (2023). Oral transmucosal fentanyl. In StatPearls. Treasure Island, FL: StatPearls Publishing. (NCBI)
5. Unknown author. (n.d.). Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Medicine. (Oxford Academic)
6. Unknown author. (n.d.). Single-dose pharmacokinetics of fentanyl sublingual spray. Clinical Therapeutics. (Clinical Therapeutics)
7. Unknown author. (n.d.). Absolute and relative bioavailability of fentanyl buccal tablet. Journal of Clinical Pharmacology. (Wiley Online Library)
8. Elsner, F., Zeppetella, G., Porta-Sales, J., & Tagarro, I. (2011). Newer generation fentanyl transmucosal products for breakthrough pain in opioid tolerant cancer patients. Clinical Drug Investigation, 31(9), 605–618. (e-jyms.org)
9. Unknown author. (2006). Evidence-based oral transmucosal fentanyl citrate dosing guidelines. Pain Medicine, 6(4), 305–314. (Oxford Academic)
10. Unknown. (2003). Comparison of two simultaneous 400 μg doses with a single 800 μg dose of oral transmucosal fentanyl citrate. Journal of Pain and Symptom Management. (JPSM Journal)
11. Janknegt, R., van den Beuken, M., & Überall, M. (2018). Rapid-acting fentanyl formulations in breakthrough cancer pain: A hospital pharmacy analysis. European Journal of Hospital Pharmacy, 25(3), e2. https://doi.org/10.1136/ejhpharm-2016-001127 (PubMed)
12. Borges, F. M., & Rosenberg, J. (2000). Oral transmucosal fentanyl citrate in breakthrough pain treatment. Ugeskrift for Laeger, 162(39), 5237–5240. (PubMed)
13. Portenoy, R. K., Payne, R., & Coluzzi, P. (1999). Oral transmucosal fentanyl citrate for breakthrough cancer pain: A controlled titration study. Pain, 79(2–3), 303–312. https://doi.org/10.1016/S0304-3959(98)00179-1 (PubMed)
14. Lee, M., Kern, S. E., Kisicki, J. C., & Egan, T. D. (2003). Pharmacokinetic study comparing simultaneous 400 μg vs single 800 μg dose of OTFC. Journal of Pain and Symptom Management. (JPSM Journal)
15. Sattar, M., Ahmad, M., Swami, M., & Ali, J. (2014). Buccal mucoadhesive drug delivery: A promising option for low-bioavailability drugs. Journal of Applied Pharmaceutical Science, 4(2), 45–50.
16. Nakhaee, S., Saeedi, F., & Mehrpour, O. (2023). Clinical and pharmacokinetic overview of intranasal fentanyl administration. Heliyon. (Wikipedia)
17. Lim, C. B. S., Schug, S. A., Sunderland, V. B., Paech, M. J., & Liu, Y. (2010). Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Medicine. (Wikipedia)
18. Taylor, D. (2013). Single-dose fentanyl sublingual spray for breakthrough cancer pain. Clinical Pharmacology: Advances and Applications. (Wikipedia)
19. Varvel, J. R., Shafer, S. L., Hwang, S. S., Coen, P. A., & Stanski, D. R. (1989). Absorption characteristics of transdermally administered fentanyl. Anesthesiology, 70(6), 1049–1056. (Wikipedia)
20. Wikipedia contributors. (2025, July). Buccal administration. In Wikipedia, The Free Encyclopedia. https://en.wikipedia.org/wiki/Buccal_administration (Wikipedia).